Provided by Tiger Trade Technology Pte. Ltd.

NRX Pharmaceuticals Inc. Warrant

0.0385
-0.0015-3.88%
Volume:30.67K
Turnover:1.23K
Market Cap:757.66K
PE:-0.02
High:0.0450
Open:0.0414
Low:0.0369
Close:0.0400
52wk High:0.1751
52wk Low:0.0293
Shares:19.71M
Float Shares:19.71M
Volume Ratio:2.77
T/O Rate:0.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3221
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Company Profile

Company Name:
NRX Pharmaceuticals Inc. Warrant
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.